DanCann Pharma A/S to be inspected by the Danish Medicines Agency in Q4 2022: EU-GMP approval expected by the end of 2022
earlier this year
The company is now ready for inspection.
– EU-GMP certification of a facility is recognition of our work and is an important step in achieving quality-assured products for our partners and ultimately patients. This is essential to our legitimacy in the market. By focusing on unified product content and delivering the same quality every time,
BP1 is built on pharmaceutical industry best practices that combine advanced controlled-environment manufacturing techniques with vertical cultivation. Selected genetics are developed in a multi-layered system without the use of soil or other media, but with a specially developed system that adds the required amount of liquids and nutrients.
– Acknowledgment marks an important and decisive step in the journey.
After facility approval,
For more information, please visit www.dancann.com.
For more information, please contact:
Certain statements in this release may contain forward-looking information. All statements, other than historical facts, that address future activities, events or developments that the Company believes, expects or anticipates will occur or may occur (potential acquisitions and financing statements, including but not limited to statements regarding, are forward-looking statements. statement. Forward-looking statements generally use the words “may,” “will,” “should,” “continue,” “expect,” “project,” “estimate,” and “believe.” ‘, ‘intend’, and ‘plan’. ‘ or ‘project’, or the negation of these words, or other variations of these words, or equivalent terms.
Forward-looking statements are subject to a number of risks and uncertainties. Many of these are beyond our ability to control or predict and could cause our actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, our inability to obtain sufficient funds to execute our business plans; is not limited to competition; regulatory and anticipated and unanticipated costs and delays, success of the company’s research strategy, applicability of discoveries made therein, successful and timely completion and uncertainty related to the regulatory process, regulatory or intellectual the timing and consequences of property decisions and other risks disclosed in our public disclosure records filed with relevant securities regulators;
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those set forth in the forward-looking statements, it is Or there may be other factors that cause it to be different than intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements contained in this presentation are made as of the date of this presentation and the Company may not reflect new information, subsequent events or otherwise, unless required by applicable securities laws. does not undertake any obligation to publicly update such forward-looking statements.
(c) Sision 2022. all rights reserved.sauce